The Legal Examiner Mark The Legal Examiner Mark The Legal Examiner Mark search twitter facebook feed linkedin instagram google-plus avvo phone envelope checkmark mail-reply spinner error close
Skip to main content

Schwarz Pharma Inc., a unit of Belgium’s UCB SA, has agreed to pay $22 million to resolve allegations that it claimed federal reimbursements for unapproved medications, say federal prosecutors.

The company allegedly submitted false reports and was accused of failing to advise The Centers for Medicare and Medicaid Services (CMS) that two unapproved medications [Deponit and Hyoscyamine Sulfate ER] were not eligible for reimbursement under federal health programs.

Both drugs have ever received full regulatory approval and neither is on the market, the Justice Department said.

Comments are closed.

Of Interest